Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Class A ordinary share, par value $0.0001 per share
-
Shares outstanding
-
71,400,541
-
Total 13F shares
-
39,419,149
-
Share change
-
+1,669,713
-
Total reported value
-
$843,176,754
-
Price per share
-
$21.39
-
Number of holders
-
43
-
Value change
-
+$59,244,738
-
Number of buys
-
31
-
Number of sells
-
17
Institutional Holders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) as of Q1 2023
As of 31 Mar 2023,
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,419,149 shares.
The largest 10 holders included
BVF INC/IL, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Polar Capital Holdings Plc, PRICE T ROWE ASSOCIATES INC /MD/, FEDERATED HERMES, INC., RTW INVESTMENTS, LP, FMR LLC, and JPMORGAN CHASE & CO.
This page lists
43
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.